Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

PURPOSE: Chimeric antigen receptor (CAR) T-cell therapies have shown clinical benefit for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), yet approximately 60% of patients do not respond or eventually relapse. We investigated the safety and feasibility of the CD19-directed CAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Michael D., Miklos, David B., Jacobson, Caron A., Timmerman, John M., Sun, Jennifer, Nater, Jenny, Fang, Xiang, Patel, Ankit, Davis, Madison, Heeke, Darren, Trinh, Tan, Mattie, Mike, Neumann, Frank, Kim, Jenny J., To, Christina, Filosto, Simone, Reshef, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570684/
https://www.ncbi.nlm.nih.gov/pubmed/37527011
http://dx.doi.org/10.1158/1078-0432.CCR-23-0916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570684/
https://www.ncbi.nlm.nih.gov/pubmed/37527011
http://dx.doi.org/10.1158/1078-0432.CCR-23-0916

Ejemplares similares